Why Do They Swab Your Nose Before Surgery?

That quick nasal swab before surgery is a screening test for a bacterium called Staphylococcus aureus, commonly known as staph. Roughly a third of the population carries it in their nose without any symptoms, and those carriers face a substantially higher risk of developing a post-surgical infection caused by their own bacteria. Hospitals swab your nose so they can identify carriers ahead of time and treat the colonization before the scalpel ever touches skin, a process called decolonization. The science behind this practice, including who benefits most and where the evidence gets complicated, goes deeper than the swab itself.

What They Are Looking For

Staphylococcus aureus lives harmlessly in the nostrils of a large chunk of the population. A U.S. national survey estimated that about 86.9 million people, or roughly 32% of the population, were nasal carriers of S. aureus, with about 0.84% carrying the antibiotic-resistant strain known as MRSA.¹ Other estimates put the global figure at up to 30% of the population being persistently colonized.² These people feel perfectly fine. The bacteria are not causing an active infection. But their nose is essentially a reservoir, and during or after surgery, that reservoir becomes a problem.

The nose is the primary screening site because it is the densest colonization point for S. aureus on the body, and swabbing it is quick and painless. Some hospitals also swab the throat, groin, or axilla, but the anterior nares remain the standard target. Finding out whether you are a carrier before the operation gives the surgical team a window to act.

How Your Own Nose Bacteria Cause Surgical Infections

The connection between nasal carriage and post-surgical infection is not a coincidence of the same species showing up in two places. Genetic fingerprinting studies have shown that when a carrier develops a surgical site infection with S. aureus, it is almost always their own nasal strain. In orthopedic surgery patients, researchers found near-complete concordance between the genotype of the S. aureus in a carrier’s nose and the genotype recovered from a deep surgical site infection, supporting the idea that the bacteria traveled from the patient’s own body to the wound.³ Studies in cardiac surgery have confirmed the same pattern: DNA fingerprinting of S. aureus from a patient’s nose matched the strain found in infected sternal wounds and mediastinal tissue in nearly every case.⁴

The pathway is called endogenous infection. Your skin and mucous membranes harbor the bacteria, and during surgery, staph can migrate from the nose to the skin surface around the incision, or get introduced when tissues are opened. This is distinct from catching an infection from contaminated instruments or hospital staff, which of course also happens but is a separate problem. The nasal swab targets the risk you carry within yourself.

How Much Extra Risk Carriers Face

A meta-analysis of orthopedic surgery patients found that nasal carriers of S. aureus had roughly six times the odds of developing a surgical site infection compared with non-carriers.⁵ In cardiac surgery, a study of elective patients found that nasal carriage was independently associated with a dramatically elevated risk of superficial surgical site infection after accounting for other variables.⁶ Not every carrier will develop an infection, of course. But given that surgical site infections are among the most common and costly hospital-acquired complications, even a modest absolute increase in risk is worth addressing when a simple nasal swab can flag it.

What Happens If You Test Positive

If the swab comes back positive for S. aureus, you will typically be given an antibiotic ointment called mupirocin to apply inside your nostrils twice a day for about five days before the operation. Most protocols also add chlorhexidine body washes to reduce staph on the skin.⁷ The goal is not to cure you of carrying staph permanently but to temporarily clear or reduce the bacterial load at the time of surgery, shrinking the chance that the bacteria will make it into the wound.

If the swab detects MRSA specifically, the surgical team may also adjust the intravenous antibiotics you receive at the start of the operation. Standard surgical prophylaxis typically uses a beta-lactam antibiotic, which does not cover MRSA. Knowing the patient carries MRSA lets the team switch to a different drug like vancomycin. In pediatric spine surgery, for instance, preoperative MRSA screening led to antibiotic regimen changes in up to 6.5% of patients.⁸ That is a meaningful fraction of kids who would have received the wrong prophylaxis without the swab.

Patients generally tolerate the decolonization regimen well. Surveys of surgical patients undergoing screening and decolonization found few barriers to compliance and minimal side effects from mupirocin or chlorhexidine.⁹ The ointment feels greasy inside the nostrils, and chlorhexidine body wash can dry the skin, but these are mild inconveniences compared to a post-operative wound infection.

Does Decolonization Actually Reduce Infections

The evidence is strongest when you combine mupirocin with chlorhexidine bathing and target confirmed carriers. A large health technology assessment found high-quality evidence that this combination in known S. aureus carriers lowers the rate of S. aureus surgical site infections by about two-thirds compared with placebo.¹⁰ A meta-analysis focused on joint replacement surgery similarly found that screening and decolonizing carriers significantly reduced the risk of surgical site infection, prosthetic joint infection, and superficial infection.¹¹

In cardiac surgery, long-term data tells a compelling story. One center tracked its outcomes over thirteen years after introducing universal nasal decolonization. The rate of S. aureus-caused mediastinitis, a serious deep chest infection, dropped from about 1.4% to roughly 0.6% and stayed there.¹² A joint replacement program that screened and decolonized carriers before surgery saw an overall surgical site infection rate of 0.77%, compared with 1.7% in unscreened control patients.¹³

The picture is muddier when mupirocin is used alone without body washing, or when it is given universally to all patients regardless of carrier status. The same health technology assessment found that nasal mupirocin by itself may make little to no difference in surgical site infections, whether applied universally or only to known carriers.¹⁰ And at least one randomized trial in cardiac surgery carriers found that mupirocin alone did not reduce overall wound infection rates compared with placebo.¹⁴ The consensus that has emerged from this mixed evidence is that the combination of nasal mupirocin plus chlorhexidine body washes is what works, and that targeting known carriers gives the most reliable benefit.

Screen and Treat, or Just Treat Everyone

Hospitals have two basic strategies. One is “targeted decolonization,” where you swab everyone, identify the carriers, and decolonize only them. The other is “universal decolonization,” where every surgical patient gets the nasal ointment and body washes regardless of carrier status. Both have trade-offs, and the debate is ongoing.

From a pure cost perspective, treating everyone without screening can look appealing. One economic modeling study found that a treat-all approach saved an average of about $217 per operation compared with standard care, while the test-and-treat strategy saved about $123.¹⁵ A European model found even larger savings per life-year gained when treating all patients without screening.¹⁶ One study comparing the two strategies head-to-head in hip and knee replacement patients found the same overall infection rate of 0.8% for both targeted MRSA decolonization and universal decolonization.¹⁷

But universal decolonization raises a concern that many infectious disease specialists take seriously: antibiotic resistance. Exposing millions of non-carriers to mupirocin creates selection pressure for resistance. High-level mupirocin resistance has been documented spreading through coagulase-negative staphylococci, skin bacteria that are closely related to S. aureus and can share resistance genes with it.¹⁸ One study found that after mupirocin decolonization, over a third of patients who had not previously carried mupirocin-resistant bacteria acquired them.¹⁹ If mupirocin stops working because of widespread resistance, the whole decolonization strategy collapses. Universal treatment also eliminates the hospital’s ability to track emerging resistant strains through screening data.²⁰

European guidelines from the European Society of Clinical Microbiology and Infectious Diseases currently recommend screening for S. aureus before high-risk operations such as cardiothoracic and orthopedic surgery.²¹ Practice varies considerably from hospital to hospital. A survey of Austrian surgeons found that about two-thirds had some form of preoperative decolonization program in place, but the protocols ranged from treating only known carriers to decolonizing every elective surgery patient, using a variety of different antiseptic agents.

How the Swab Gets Tested

Once the swab is taken, the lab can process it in two ways. Traditional bacterial culture grows the sample on a plate and takes one to two days to return a result. The newer approach uses PCR, a molecular test that detects S. aureus DNA directly and can return a result within hours. Speed matters because many elective surgeries are scheduled only days in advance, and a five-day mupirocin course has to start in time to finish before the operation.

Head-to-head comparisons show trade-offs. One study found that conventional culture had a sensitivity of about 98% for detecting nasal S. aureus, while two different PCR methods achieved about 82-86%, with the gap attributable to samples with low bacterial loads.²² However, another study found that when broth enrichment was added to culture, culture actually became less sensitive than a newer PCR assay for detecting MRSA (about 77% versus 97%), and the PCR test allowed faster implementation of appropriate prophylaxis.²³ The bottom line for patients is that both methods are well established, and your hospital’s choice between them usually reflects local lab capacity and scheduling logistics more than a fundamental difference in quality.

The Limits of a Single Nose Swab

A single nasal swab is good but not perfect. Some people carry S. aureus intermittently, meaning they might test negative on the day of the swab but positive a week later. A longitudinal study that followed individuals over four weeks found that a positive first swab had an 88% positive predictive value for persistent carriage, and a negative first swab had a 97% negative predictive value, meaning most negatives stay negative.²⁴ That 97% figure is reassuring, but it also means a small percentage of carriers slip through.

The nose is not the only colonization site. When researchers screened patients using additional body sites and more sensitive culture methods, carrier prevalence rose from 35% with routine nasal screening to 42%.²⁵ Some people carry staph in the throat, groin, or perineum but not the nose. For practical purposes, adding throat or groin swabs improves detection, but it also adds cost and complexity. Most hospitals accept the nose-only approach as a reasonable trade-off between sensitivity and feasibility.

Nasal Swabs for Respiratory Viruses Before Surgery

In some hospitals, particularly since the COVID-19 pandemic, you might also be swabbed for respiratory viruses before surgery. This is a distinct test from the S. aureus screen, though the mechanics feel the same. The rationale is different: an active respiratory virus could complicate anesthesia, affect lung function during and after surgery, or pose an infection control risk to staff and other patients.

How much a positive viral swab changes surgical outcomes is still being studied. A study of children undergoing congenital heart surgery found that about 29% of those who had routine preoperative viral testing came back positive, but there were no significant differences in surgical outcomes, including mortality, between virus-positive and virus-negative groups.²⁶ That does not mean the screening is pointless. Even if outcomes do not differ dramatically in some studies, knowing a patient has an active virus lets the team take precautions with airway management and isolation. The clinical value depends on the specific virus, the type of surgery, and the patient’s overall health.

What Decolonization Does to Your Nasal Microbiome

Your nose is not just home to S. aureus. It hosts a whole community of bacteria that normally coexist in balance. When mupirocin is applied to clear staph, it does not leave the rest of the community untouched. Research tracking the nasal microbiome before and after decolonization found that mupirocin wiped out not only S. aureus but also other susceptible species like S. epidermidis, Dolosigranulum pigrum, and Moraxella nonliquefaciens, while naturally resistant species like certain corynebacteria and Cutibacterium acnes remained and expanded into the vacated space.²⁷

This reshuffling may actually help keep S. aureus away after treatment. There is evidence that coagulase-negative staphylococci, which regrow quickly after mupirocin treatment, are natural competitors of S. aureus. Their return to the nasal niche may help suppress recolonization.²⁸ It is an interesting wrinkle: the disruption caused by the antibiotic ointment might indirectly extend the benefit by giving friendly competitors a head start in recolonizing the nose. That said, how long the effect lasts varies from person to person, and some people are recolonized with S. aureus within weeks.

Alternatives to Mupirocin on the Horizon

With concerns about mupirocin resistance growing, researchers have been testing alternatives. Povidone-iodine, an antiseptic rather than an antibiotic, is already used at some centers. A randomized trial comparing nasal povidone-iodine to mupirocin found comparable rates of deep surgical site infections, with the per-protocol analysis actually favoring povidone-iodine for S. aureus deep infections.²⁹ Povidone-iodine has the advantage of being cheap, fast-acting, and unlikely to drive the kind of targeted resistance that mupirocin does.

A more novel approach is antimicrobial photodynamic therapy, which uses a light-activated dye to kill bacteria inside the nostrils. A pilot trial in hemodialysis patients found that photodynamic therapy cleared nasal S. aureus at a rate comparable to mupirocin, with about 71% achieving negative cultures immediately after treatment versus 77% for mupirocin, and no adverse events in the photodynamic therapy group.³⁰ In spine surgery, a program that combined nasal photodynamic disinfection with chlorhexidine body wipes cut the annual surgical site infection rate from about 8% to under 3%.³¹ These alternatives are not yet standard practice everywhere, but they represent a hedge against the day mupirocin resistance becomes widespread enough to undermine current protocols.

When the Swab Might Not Apply to You

Not every surgery triggers a nasal swab. Screening is most consistently used before high-risk procedures where an implant is being placed or where the consequences of infection are severe: joint replacements, cardiac surgery, spinal fusion, and other operations involving hardware. For minor outpatient procedures or surgeries with low baseline infection rates, the cost-benefit calculation is different and many hospitals skip the screen.

The cost of screening itself is modest. One analysis found that nasal screening for total knee and hip arthroplasty cost about $144 per patient and became cost-effective with even a very small reduction in infection rates.³² The decolonization treatment itself costs as little as $5 for the most basic mupirocin regimen. Compared to the cost of treating a surgical site infection, which can run into tens of thousands of dollars and weeks of additional treatment, the economics strongly favor screening in any surgery with a meaningful baseline infection risk. If you are having a procedure that involves an implant and no one mentions a nasal swab, it is entirely reasonable to ask whether screening is part of the protocol.